Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
ACADEMIA
Chiba University Weighs Asking University of Tokyo to Punish VART Chief Investigator
Chiba University will consider requesting the University of Tokyo to impose penalties on Issei Komuro, who is now at Japan’s most prestigious university, over a botched clinical trial he led on Novartis Pharma’s blood pressure drug Diovan (valsartan). In its…
To read the full story
Related Article
- Japan Hypertension Society to Retract Diovan Paper on VART Study
August 16, 2016
- Chiba Univ. Finds Dropout Rates of 60-80% in Secondary Endpoints, Raps VART Study as “Absolutely Unreliable”
July 16, 2014
- Chiba Univ. Advises Authors to Withdraw VART Papers
May 26, 2014
- Claims of Superior Cardiorenal Protective Effects of Diovan “Cannot Be Supported”: Outside Investigation of VART Study
April 30, 2014
- Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
ACADEMIA
- Refusal to See Patients due to Kostaive Shots Might Violate “Duty of Care”: Lawyer
December 17, 2024
- Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
December 6, 2024
- Consortium on Pediatric Drug Development Up and Running from This Fiscal Year
November 25, 2024
- Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan
November 8, 2024
- Alzheimer’s-Related Guidelines Being Revised to Accommodate Kisunla, Rexulti
November 6, 2024
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…